Converging quality by design, artificial intelligence, and biofoundry automation: A new paradigm for scalable...

Synthetic biology applies engineering principles to the rational design of biological systems with the aim of producing predictable and tunable behaviour. Although the field's conceptual foundations and core technologies are well established, the recent simultaneous maturation of Quality by Design (QbD), artificial intelligence (AI)-assisted biological design, and automated biofoundry workflows is beginning to outline a more replicable pathway from laboratory innovation to industrial-scale circular biomanufacturing. This review argues that the convergence of these three elements, rather than any one alone, characterises the current phase of the field. We examine how the Design-Build-Test-Learn (DBTL) cycle is being transformed from a research heuristic into a systematic industrial development framework; show how shared toolsets now transfer across microbial, plant, and animal systems to enable a holistic bioeconomy; benchmark synthetic biology-derived products against conventional alternatives where techno-economic and life-cycle data permit; and examine scale-up, regulatory, and societal bottlenecks through recent market-scale case studies in which these bottlenecks have been navigated in practice. We also contrast EU and US regulatory frameworks to show how policy divergence shapes technology adoption. We conclude by identifying what the coming decade of convergent synthetic biology must deliver to support a circular bioeconomy at the scale the 2030 Agenda demands.